| NOVAVAX INC. DL-,01 |
| USA |
| Gesundheit |
| US6700024010 / A2PKMZ |
| NVV1 (Frankfurt) |
| FRA:NVV1, ETR:NVV1, NVV1:GR |
| - |
| https://novavax.com/ |
|
Novavax Inc. is a biotechnology company that engages in the discovery, development, and commercialization of recombinant vaccines to protect against serious infectious diseases. It specializes in protein-based vaccine platforms, including its proprie..
>Volltext.. |
| 1305.28 Mio. EUR |
| 876.12 Mio. EUR |
| 513.97 Mio. EUR |
| 51.33 Mio. EUR |
| -75.7 Mio. EUR |
| -0.46 EUR |
| 254.3 Mio. EUR |
| 196.82 Mio. EUR |
| - |
| 2.31 |
| -55.51% |
| -117.18% |
| - |
| - |
| - |
| - |
| NOVAVAX |
| 26.05.26 |